Replimune Group Inc (NASDAQ:REPL) saw a significant growth in short interest in October. As of October 31st, there was short interest totalling 635,300 shares, a growth of 14.2% from the September 30th total of 556,300 shares. Based on an average trading volume of 59,000 shares, the short-interest ratio is presently 10.8 days. Approximately 8.0% of the company’s shares are short sold.
Shares of REPL stock traded down $1.44 on Friday, hitting $12.20. The stock had a trading volume of 819,800 shares, compared to its average volume of 194,376. The firm has a market capitalization of $436.60 million, a price-to-earnings ratio of -9.17 and a beta of 3.30. Replimune Group has a 52-week low of $8.88 and a 52-week high of $18.25. The stock’s 50 day moving average is $14.49 and its 200-day moving average is $13.44. The company has a debt-to-equity ratio of 0.16, a quick ratio of 9.79 and a current ratio of 9.85.
Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Monday, November 11th. The company reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.01). Equities analysts expect that Replimune Group will post -1.4 earnings per share for the current year.
Several equities research analysts have recently issued reports on the stock. Roth Capital increased their price objective on shares of Replimune Group from $20.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, November 11th. Chardan Capital reissued a “buy” rating and issued a $28.00 price objective on shares of Replimune Group in a research report on Thursday, October 24th. Zacks Investment Research lowered shares of Replimune Group from a “buy” rating to a “hold” rating in a research report on Friday. ValuEngine upgraded shares of Replimune Group from a “sell” rating to a “hold” rating in a research note on Monday, November 4th. Finally, HC Wainwright restated a “buy” rating and issued a $26.00 target price on shares of Replimune Group in a research note on Monday, September 30th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $25.17.
In other news, COO Colin Love sold 11,250 shares of the stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $17.05, for a total value of $191,812.50. Also, CEO Robert Coffin sold 48,500 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $16.92, for a total transaction of $820,620.00. Insiders sold 200,000 shares of company stock valued at $3,395,500 in the last three months. Company insiders own 63.18% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in REPL. BlackRock Inc. increased its holdings in shares of Replimune Group by 8.2% in the 2nd quarter. BlackRock Inc. now owns 1,015,225 shares of the company’s stock worth $14,883,000 after acquiring an additional 76,540 shares during the period. Vanguard Group Inc. increased its holdings in shares of Replimune Group by 7.3% in the 2nd quarter. Vanguard Group Inc. now owns 536,564 shares of the company’s stock worth $7,866,000 after acquiring an additional 36,547 shares during the period. Emerald Advisers LLC increased its holdings in shares of Replimune Group by 5.2% in the 3rd quarter. Emerald Advisers LLC now owns 728,890 shares of the company’s stock worth $10,132,000 after acquiring an additional 35,712 shares during the period. Foresite Capital Management III LLC increased its holdings in shares of Replimune Group by 4.0% in the 2nd quarter. Foresite Capital Management III LLC now owns 779,656 shares of the company’s stock worth $11,430,000 after acquiring an additional 30,002 shares during the period. Finally, Emerald Mutual Fund Advisers Trust increased its holdings in shares of Replimune Group by 3.0% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 733,404 shares of the company’s stock worth $10,194,000 after acquiring an additional 21,634 shares during the period. 60.92% of the stock is currently owned by institutional investors and hedge funds.
About Replimune Group
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.
Featured Story: Using other technical indicators with support levels
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.